SuperworthHaemonetics profit margin HAE
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- 7.1%
- Operating margin, 12 months
- 11.9%
- Net margin on a year earlier
- −5.0 pts
- Peer median
- 10.3%
Over the twelve months to Jun 27, 2026, Haemonetics kept 7.1% of its revenue as net profit, with an operating margin of 11.9% and a gross margin of 59.0%.
Five years earlier its net margin was 7.1%.
The median for 10 medical instruments and supplies stocks of a similar size is 10.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2026 | 7.3% | 11.7% | 59.0% |
| FY2025 | 12.3% | 16.3% | 55.0% |
| FY2024 | 9.0% | 12.6% | 52.8% |
| FY2023 | 9.9% | 13.4% | 52.6% |
| FY2022 | 4.4% | 8.1% | 50.9% |
| FY2021 | 9.1% | 10.3% | 45.7% |
| FY2020 | 7.7% | 10.5% | 49.0% |
| FY2019 | 5.7% | 8.6% | 43.2% |
| FY2018 | 5.0% | 6.2% | 45.6% |
| FY2017 | −3.0% | −2.2% | 42.7% |
| FY2016 | −6.1% | −4.8% | 44.7% |
| FY2015 | 1.9% | 4.5% | 47.7% |
| FY2014 | 3.7% | 4.9% | 49.9% |
| FY2013 | 4.3% | 6.3% | 48.0% |
| FY2012 | 9.2% | 12.2% | 50.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q1 FY27 | 7.1% | −5.0 pts | 11.9% | |
| Q4 FY26 | 7.3% | −5.0 pts | 11.7% | |
| Q3 FY26 | 13.3% | +3.8 pts | 19.0% | |
| Q2 FY26 | 12.7% | +3.6 pts | 18.3% | |
| Q1 FY26 | 12.1% | +3.5 pts | 17.5% | |
| Q4 FY25 | 12.3% | +3.3 pts | 16.3% | |
| Q3 FY25 | 9.5% | −0.5 pts | 13.1% | |
| Q2 FY25 | 9.1% | −1.3 pts | 12.3% | |
| Q1 FY25 | 8.6% | −2.6 pts | 11.3% | |
| Q4 FY24 | 9.0% | −0.9 pts | 12.6% | |
| Q3 FY24 | 10.0% | +1.5 pts | 13.4% | |
| Q2 FY24 | 10.4% | +2.4 pts | 13.5% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Haemonetics' size, closest first, today.
| Company | Profit margin |
|---|---|
| HAEHaemonetics | 7.1% |
| MMSIMerit Medical Systems | 9.2% |
| VNTVontier | 11.3% |
| BMIBadger Meter | 14.3% |
| ICUIICU Medical | 1.4% |
| MSAMSA Safety | 16.1% |
| NVSTEnvista | 3.3% |
| WRBYWarby Parker | 0.8% |
| ATRCAtriCure | 1.9% |
| PODDInsulet | 12.3% |
| GMEDGlobus Medical | 17.0% |
| Peer median | 10.3% |
Where Haemonetics ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Haemonetics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.